TimesSquare Capital Management’s CG Oncology CGON Stock Holding History

TimesSquare Capital Management’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15M	Sell	210,884 -42,824	-17%	-$2.8M	0.22%	128
2026 Q1	$17.2M	Sell	253,708 -172,311	-40%	-$9.76M	0.29%	114
2025 Q4	$17.7M	Sell	426,019 -77,507	-15%	-$3.21M	0.27%	121
2025 Q3	$20.3M	Sell	503,526 -8,675	-2%	-$252K	0.29%	119
2025 Q2	$13.3M	Sell	512,201 -5,057	-1%	-$122K	0.19%	130
2025 Q1	$12.7M	Sell	517,258 -29,646	-5%	-$834K	0.2%	129
2024 Q4	$15.7M	Buy	546,904 +109,835	+25%	+$3.76M	0.23%	126
2024 Q3	$16.5M	Buy	437,069 +94,010	+27%	+$3.3M	0.25%	125
2024 Q2	$10.8M	Buy	343,059 +118,986	+53%	+$4.12M	0.17%	135
2024 Q1	$9.84M	Buy	+224,073	New	+$9.15M	0.14%	143

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TimesSquare Capital Management's CGON Position: Q2 2026 in Review

TimesSquare Capital Management reduced its CG Oncology (CGON) stake by 17% in Q2 2026, selling an estimated $2.8M and leaving 210,884 shares worth $15M. The position accounts for 0.22% of the portfolio, ranked #128.

TimesSquare Capital Management first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. The position peaked at $20.3M in Q3 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

TimesSquare Capital Management held 210,884 shares of CG Oncology worth $15M as of Q2 2026.
TimesSquare Capital Management sold 42,824 CG Oncology shares in Q2 2026, an estimated $2.8M.
CG Oncology made up 0.22% of TimesSquare Capital Management's portfolio in Q2 2026, its #128 holding.
TimesSquare Capital Management first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
TimesSquare Capital Management's CG Oncology position peaked at $20.3M in Q3 2025.
227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on TimesSquare Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.